Overview

A Study to Evaluate the Efficacy and Safety of Bimekizumab Compared to Placebo and an Active Comparator in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis

Status:
Completed

Trial end date:
2019-12-13

Target enrollment:

Participant gender:

Summary

This is a study to compare the efficacy of bimekizumab versus placebo and an active comparator in the treatment of subjects with moderate to severe chronic plaque psoriasis (PSO).

Phase:

Phase 3

Details

Lead Sponsor:

UCB Biopharma S.P.R.L.

Treatments:

Ustekinumab